Showing results (2021-2030 of 2,065) with videos related to
Sort By:
Pageof 207
Genome Medicine|April 14, 2025
Systematic identification of disease-causing promoter and untranslated region variants in 8040 undiagnosed individuals with rare diseaseAlexandra C Martin-Geary, Alexander J M Blakes, Ruebena Dawes, et al.Cambridge Prisms. Precision Medicine|November 27, 2025
Accelerating eSource scale-up in oncology clinical trials: The i~HD Task Force initiativeChristophe Maes, Dipak Kalra, Tracy Acito, et al.ESMO Gastrointestinal Oncology|February 6, 2026
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trialJ Lee, A Dean, T Price, et al.Nature Communications|July 6, 2016
Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analysesKatannya Kapeli, Gabriel A Pratt, Anthony Q Vu, et al.BMJ Open|September 20, 2022
The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancerJuliet A Usher-Smith, Angela Godoy, Sarah W Burge, et al.The European Respiratory Journal|February 2, 2008
Outcomes for COPD pharmacological trials: from lung function to biomarkersM Cazzola, W MacNee, F J Martinez, et al.International Journal of Cancer|September 28, 2020
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studiesJeanne Tie, Joshua D Cohen, Serigne N Lo, et al.Nature Medicine|March 7, 2025
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trialJeanne Tie, Yuxuan Wang, Serigne N Lo, et al.Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.The New England Journal of Medicine|June 3, 2022
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerJeanne Tie, Joshua D Cohen, Kamel Lahouel, et al.Pageof 207